Cumulative dose of bevacizumab associates with albuminuria rather than podocyturia in cancer patients-Reference-Cited by-同舟云学术

Cumulative dose of bevacizumab associates with albuminuria rather than podocyturia in cancer patients

Published:2018-11 Issue:11 Volume:12 Page:e1-e7
ISSN:1933-1711
Container-title:Journal of the American Society of Hypertension
language:en
Short-container-title:Journal of the American Society of Hypertension

Author:

Lankhorst Stephanie,Baelde Hans J.,Verstijnen Jose A.M.C.,ten Tije Albert J.,Thelen Marc H.M.,Danser A.H. Jan,van den Meiracker Anton H.,Kappers Mariëtte H.W.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Internal Medicine

Reference25 articles.

1. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer;Hurwitz;Clin Colorectal Cancer,2004

2. An overview of small-molecule inhibitors of VEGFR signaling;Ivy;Nat Rev Clin Oncol,2009

3. Mechanism of hypertension and proteinuria during angiogenesis inhibition: Evolving role of endothelin-1;Lankhorst;J Hypertens,2013

4. Bevacizumab added to neoadjuvant chemotherapy for breast cancer;Bear;N Engl J Med,2012

5. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ecog 4599;Dahlberg;J Clin Oncol,2010

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differential effects of cyclo-oxygenase 1 and 2 inhibition on angiogenesis inhibitor-induced hypertension and kidney damage;Clinical Science;2022-05

2. Novel function of adrenocorticotropic hormone in the stimulation of vascular endothelial growth factor release in healthy children and adolescents: a proof-of-concept study;Annals of Pediatric Endocrinology & Metabolism;2021-03-31